Cited by 1,280Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 322 of the 322 references it cites were found in a registry or an index.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Open access

Lindeman, Neal I., Cagle, Philip T., Beasley, Mary Beth, Chitale, Dhananjay Arun, Dacic, Sanja, Giaccone, Giuseppe, Jenkins, Robert Brian, Kwiatkowski, David J., Saldivar, Juan-Sebastian, Squire, Jeremy, Thunnissen, Erik, Ladanyi, Marc·2013·Journal of Thoracic Oncology

DOI 10.1097/jto.0b013e318290868fPMC PMC4159960

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE: To establish evidence-based recommendations for the molecular analysis of lung cancers that are that are required to guide EGFR- and ALK-directed therapies, addressing which patients and samples should be tested, and when and how testing should be performed. PARTICIPANTS: Three cochairs without conflicts of interest were selected, one from each of the 3 sponsoring professional societies: College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Writing and advisory panels were constituted from additional experts from these societies. EVIDENCE: Three unbiased literature searches of electronic databases were performed to capture articles published published from January 2004 through February 2012, yielding 1533 articles whose abstracts were screened to identify 521 pertinent articles that were then reviewed in detail for their relevance to the recommendations. Evidence was formally graded for each recommendation. CONSENSUS PROCESS: Initial recommendations were formulated by the cochairs and panel members at a public meeting. Each guideline section was assigned to at least 2 panelists. Drafts were circulated to the writing panel (version 1), advisory panel (version 2), and the public (version 3) before submission (version 4). CONCLUSIONS: The 37 guideline items address 14 subjects, including 15 recommendations (evidence grade A/B). The major recommendations are to use testing for EGFR mutations and ALK fusions to guide patient selection for therapy with an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitor, respectively, in all patients with advanced-stage adenocarcinoma, regardless of sex, race, smoking history, or other clinical risk factors, and to prioritize EGFR and ALK testing over other molecular predictive tests. As scientific discoveries and clinical practice outpace the completion of randomized clinical trials, evidence-based guidelines developed by expert practitioners are vital for communicating emerging clinical standards. Already, new treatments targeting genetic alterations in other, less common driver oncogenes are being evaluated in lung cancer, and testing for these may be addressed in future versions of these guidelines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e318290868f

Cites

322 of 322 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–322 of 322

Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis
Boldrini, L., Gisfredi, S., Ursino, S., Camacci, T., Baldini, E., Melfi, F. M. A., & Fontanini, G. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815ba1fa · Cited by 100
Use of Epidermal Growth Factor Receptor/Kirsten Rat Sarcoma 2 Viral Oncogene Homolog Mutation Testing to Define Clonal Relationships Among Multiple Lung Adenocarcinomas
Girard, N., Deshpande, C. G., Azzoli, C. G., Rusch, V. W., Travis, W. D., Ladanyi, M., & Pao, W. J. (2009) · CHEST Journal · doi:10.1378/chest.09-0325 · Cited by 99
Self-citation
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
Kim, S. T., Uhm, J. E., Lee, J., Sun, J., Sohn, I., Kim, S. W., Jung, S., Park, Y. H., Ahn, J. S., Park, K., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.05.022 · Cited by 99
Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas
Tang, X., Varella‐Garcia, M., Xavier, A. C., Massarelli, E., Ozburn, N. C., Moran, C. A., & Wistuba, I. I. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0032 · Cited by 99
Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR
Santis, G., Angell, R., Nickless, G., Quinn, A., Herbert, A., Cane, P., Spicer, J. F., Breen, R. A. M., McLean, E., & Tobal, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025191 · Cited by 99
Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer
Horiike, A., Kimura, H., Nishio, K., et al. (2007) · CHEST Journal · doi:10.1378/chest.06-1673 · Cited by 99
Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas
Soung, Y. H., Lee, J. W., Kim, S. Y., Seo, S. H., Park, W. S., Nam, S. W., Song, S. Y., Han, J. H., Park, C. K., Lee, J. Y., et al. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-1254-y · Cited by 97
Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers
Lee, S. Y., Kim, M. J., Jin, G., Yoo, S. S., Park, J. Y., Choi, J. E., Jeon, H. S., Cho, S., Lee, E. B., Cha, S. I., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f0beca · Cited by 97
Genetic Abnormalities of the EGFR Pathway in African American Patients With Non–Small-Cell Lung Cancer
Leidner, R. S., Fu, P., Clifford, B. T., Hamdan, A., Jin, C., Eisenberg, R., Boggon, T. J., Skokan, M. C., Franklin, W. A., Cappuzzo, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1431 · Cited by 95
Section E9 of the American College of Medical Genetics technical standards and guidelines: Fluorescence in situ hybridization
Mascarello, J. T., Hirsch, B. A., Kearney, H. M., Ketterling, R. P., Olson, S. B., Quigley, D. I., Rao, K. W., Tepperberg, J. H., Tsuchiya, K. D., & Wiktor, A. E. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182227295 · Cited by 95
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer
Feng, Y., Thiagarajan, P. S., & Ma, P. C. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182417e44 · Cited by 93
Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation
Blons, H., Côté, J.-F., Corre, D. L., Riquet, M., Fabre, E., Laurent‐Puig, P., & Danel, C. J. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213285.65907.31 · Cited by 93
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
Yang, J. C., Schüler, M., Yamamoto, N., O'Byrne, K. J., Hirsh, V., Mok, T. S. K., Geater, S. L., Orlov, S., Tsai, C., Boyer, M. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.lba7500 · Cited by 93
The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors
Engelman, J. A., & Cantley, L. C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0795 · Cited by 92
PCR artifacts in LOH and MSI analysis of microdissected tumor cells
Sieben, N. L. G., ter Haar, N. T., Cornelisse, C. J., et al. (2000) · Human Pathology · doi:10.1016/s0046-8177(00)80013-1 · Cited by 91
Rapid Detection of Epidermal Growth Factor Receptor Mutations in Lung Cancer by the SMart-Amplification Process
Hoshi, K., Takakura, H., Mitani, Y., Tatsumi, K., Momiyama, N., Ichikawa, Y., Togo, S., Miyagi, T., Kawai, Y., Kogo, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0509 · Cited by 90
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
Sugio, K., Uramoto, H., Onitsuka, T., Mizukami, M., Ichiki, Y., Sugaya, M., Yasuda, M., Takenoyama, M., Oyama, T., Hanagiri, T., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.09.010 · Cited by 89
Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma
Shimizu (2011) · Oncology Reports · doi:10.3892/or.2011.1182 · Cited by 88
Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)--HCFA. Final rule with comment period.
(1992) · PubMed · Cited by 86
EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC
Penzel, R., Sers, C., Chen, Y., Lehmann-Mühlenhoff, U., Merkelbach‐Bruse, S., Jung, A., Kirchner, T., Büttner, R., Kreipe, H. H., Petersen, I., et al. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-1000-y · Cited by 85
Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study
Macarenco, R., Uphoff, T. S., Gilmer, H. C. F., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.113 · Cited by 85
The Application of Molecular Diagnostic Studies Interrogating EGFR and KRAS Mutations to Stained Cytologic Smears of Lung Carcinoma
Betz, B. L., Roh, M. H., Weigelin, H. C., Placido, J. B., Schmidt, L. A., Farmen, S., Arenberg, D. A., Kalemkerian, G. P., & Knoepp, S. M. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcp84tutqosuong · Cited by 85
Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice
Sun, L., Zhang, Q., Luan, H., et al. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-30 · Cited by 84
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
Dufort, S., Richard, M., Lantuéjoul, S., & de Fraipont, F. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-57 · Cited by 84
Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung
Fukui, T., Tsuta, K., Furuta, K., WATANABE, S.-I. I., Asamura, H., Ohe, Y., Maeshima, A. M., Shibata, T., Masuda, N., & Matsuno, Y. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00600.x · Cited by 83
EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients
Bae, N. C., Chae, M. H., Lee, M. H., Kim, K. M., Lee, E. B., Kim, C. H., Park, T. I., Han, S. B., Jheon, S., Jung, T. H., et al. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.10.007 · Cited by 82
PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients
Endoh, H., Yatabe, Y., Kosaka, T., Kuwano, H., & Mitsudomi, T. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30374-9 · Cited by 82
Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications
Wu, C., Hsu, H., Liu, H., Chang, J. W., Chen, Y., Hsieh, W.-Y., Hsieh, J., Hsieh, M., Chen, Y., & Huang, S. (2008) · Cancer · doi:10.1002/cncr.23925 · Cited by 82
Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non–Small Cell Lung Cancer
Fukui, T., Ohe, Y., Tsuta, K., Furuta, K., Sakamoto, H., Takano, T., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5207 · Cited by 82
Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer
Hsieh, M., Fang, Y., Chang, W.-C., Kuo, H.-P., Lin, S.-Y., Liu, H.-P., Liu, C.-L., Chen, H.-C., Ku, Y.-C., Chen, Y.-T., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.06.005 · Cited by 81
Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer
Coté, M. L., Haddad, R., Edwards, D. J., Atikukke, G., Gadgeel, S. M., Soubani, A. O., Lonardo, F., Bepler, G., Schwartz, A. G., & Ethier, S. P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820a0ec0 · Cited by 81
Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation
Kuo, Y.-W., Wu, S., Ho, C., & Shih, J. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f43274 · Cited by 79
Peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp‐based detection test for gefitinib‐refractory T790M epidermal growth factor receptor mutation
Miyazawa, H., Tanaka, T., Nagai, Y., Matsuoka, M., Huqun, Sutani, A., Udagawa, K., Zhang, J., Hirama, T., Murayama, Y., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00706.x · Cited by 79
A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer
Hirsch, F. R., Kabbinavar, F. F., Eisen, T. G., Martins, R. G., Schnell, F. M., Dziadziuszko, R., Richardson, K., Richardson, F. C., Wacker, B., Sternberg, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4929 · Cited by 79
Lung Adenocarcinoma of Never Smokers and Smokers Harbor Differential Regions of Genetic Alteration and Exhibit Different Levels of Genomic Instability
Thu, K. L., Vucic, E. A., Chari, R., Zhang, W., Lockwood, W. W., English, J. C., Fu, R., Wang, P., Feng, Z., MacAulay, C. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033003 · Cited by 78
Restriction Endonuclease-Mediated Selective Polymerase Chain Reaction
Ward, R. L., Hawkins, N. J., O'grady, R., et al. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65581-2 · Cited by 76
Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas
Liang, Z., Zhang, J., Zeng, X., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-376 · Cited by 76
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers
Tiseo, M., Rossi, G., Capelletti, M., Sartori, G., Spiritelli, E., Marchioni, A., Bozzetti, C., Palma, G. D., Lagrasta, C. A., Campanini, N., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.021 · Cited by 76
EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance
Jiang, S., Yamashita, K., Yamamoto, M., Chun-ji, P., Umezawa, A., Saegusa, M., Yoshida, T., Katagiri, M., Masuda, N., Hayakawa, K., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23868 · Cited by 75
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma
Kozu, Y., Tsuta, K., Kohno, T., Sekine, I., Yoshida, A., WATANABE, S.-I. I., Tamura, T., Yokota, J., Suzuki, K., Asamura, H., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.11.003 · Cited by 75
Chromosome abnormalities in human non-small cell lung cancer.
Testa, J. R., & Siegfried, J. M. (1992) · PubMed · Cited by 74
Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes
Lozano, M. D., Zulueta, J. J., Echeveste, J. I., Gúrpide, A., Seijo, L. M., Martín‐Algarra, S., del Barrio, A., Pı́o, R., Idoate, M. A., Labiano, T., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0155 · Cited by 74
Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma
Broët, P., Dalmasso, C., Tan, E. H., Alifano, M., Zhang, S., Wu, J., Lee, M. H., Régnard, J., Lim, W., Koong, H. N., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2185 · Cited by 73
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer
Tsao, M., Sakurada, A., Ding, K., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fd83a4 · Cited by 72
Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis
Fassina, A., Gazziero, A., Zardo, D., Corradin, M., Aldighieri, E., & Rossi, G. P. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.067587 · Cited by 72
Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene
Rizvi, N. A., Rusch, V. W., Pao, W. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2102 · Cited by 70
Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma
Lee, Y. J., Park, I. K., Park, M. S., et al. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0611-7 · Cited by 70
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: Rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry
Kawahara, A., Azuma, K., Sumi, A., Taira, T., Nakashima, K., Aikawa, E., Abe, H., Yamaguchi, T., Takamori, S., Akiba, J., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.002 · Cited by 70
Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer
Jian, G., Zhou, S., Ling, Z., et al. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0785-z · Cited by 68
Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer
Hotta, K., Kiura, K., Toyooka, S., Takigawa, N., Soh, J., Fujiwara, Y., Tabata, M., Date, H., & Tanimoto, M. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318074bc0d · Cited by 67
EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors
Sartori, G., Cavazza, A., Sgambato, A., Marchioni, A., Barbieri, F., Longo, L., Bavieri, M., Murer, B., Meschiari, E., Tamberi, S., et al. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcph0trmpxvzw2f · Cited by 66
Evaluation of EGFR mutation status in cytology specimens: An institutional experience
Aisner, D. L., Deshpande, C. G., Baloch, Z. W., Watt, C. D., Litzky, L. A., Malhotra, B., Sepulveda, A. R., Langer, C. J., Evans, T. L., & Deerlin, V. M. V. (2011) · Diagnostic Cytopathology · doi:10.1002/dc.21851 · Cited by 66
A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma
Haneda, H., Sasaki, H., Lindeman, N. I., Kawano, O., Endo, K., Suzuki, E., Shimizu, S., Yukiue, H., Kobayashi, Y., Yano, M., et al. (2006) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyi228 · Cited by 65
Self-citation
Fixation and Decalcification of Adult Zebrafish for Histological, Immunocytochemical, and Genotypic Analysis
Moore, J. L., Aros, M. C., Steudel, K. G., et al. (2002) · BioTechniques · doi:10.2144/02322st03 · Cited by 64
Cytology‐based gene mutation tests to predict response to anti‐epidermal growth factor receptor therapy: A review
Malapelle, U., Bellevicine, C., Zeppa, P., Palombini, L., & Troncone, G. (2010) · Diagnostic Cytopathology · doi:10.1002/dc.21512 · Cited by 64
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer
Sone, T., Kasahara, K., Kimura, H., Nishio, K., Mizuguchi, M., Nakatsumi, Y., Shibata, K., Waseda, Y., Fujimura, M., & Nakao, S. (2007) · Cancer · doi:10.1002/cncr.22593 · Cited by 64
Detection of p53 Mutations by Single-strand Conformation Polymorphisms (SSCP) Gel Electrophoresis
Bòsari, S., Marchetti, A., Buttitta, F., et al. (1995) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199512000-00004 · Cited by 63
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma
吉基, 神. (2011) · Medical Entomology and Zoology · Cited by 63
A Panel of High Resolution Melting (HRM) Technology-Based Assays with Direct Sequencing Possibility for Effective Mutation Screening of EGFR and K-ras Genes
Heideman, D. A. M., Thunnissen, E., Doeleman, M., Kramer, D., Verheul, H. M. W., Smit, E. F., Postmus, P. E., Meijer, C. J. L. M., Meijer, G. A., & Snijders, P. J. F. (2009) · Analytical Cellular Pathology · doi:10.1155/2009/465850 · Cited by 62
Self-citation
Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry
Pintér, F., Pápay, J., Almási, A., et al. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070125 · Cited by 62
Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer
Sasaki, H., Endo, K., Okuda, K., et al. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0320-z · Cited by 61
Effects of fixation on polymerase chain reaction detection of Mycobacterium leprae
Fiallo, P., Williams, D. L., Chan, G. P., et al. (1992) · Journal of Clinical Microbiology · doi:10.1128/jcm.30.12.3095-3098.1992 · Cited by 61
Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression
Willmore‐Payne, C., Holden, J. A., & Layfield, L. J. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.02.004 · Cited by 61
Evaluation of denaturing high‐performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall‐cell lung cancer
Cohen, V., Agulnik, J. S., Jarry, J., Batist, G., Small, D. I., Kreisman, H., Tejada, N. A., Miller, W. H., & Chong, G. (2006) · Cancer · doi:10.1002/cncr.22331 · Cited by 61
Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese
Uramoto, H., Sugio, K., Oyama, T., Ono, K., Sugaya, M., Yoshimatsu, T., Hanagiri, T., Morita, M., & Yasumoto, K. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.08.006 · Cited by 59
A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes.
Heideman, D. A. M., Thunnissen, E., Doeleman, M., et al. (2009) · PubMed · doi:10.3233/clo-2009-0489 · Cited by 58
Self-citation
Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy
Bao Ming, Q. I. N., Chen, X., Zhu, J., et al. (2005) · Cell Research · doi:10.1038/sj.cr.7290289 · Cited by 57
Coamplification at Lower Denaturation Temperature-PCR Increases Mutation-Detection Selectivity of TaqMan-Based Real-Time PCR
Li, J., Wang, L., Janne, P. A., & Makrigiorgos, G. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.113381 · Cited by 57
Test Verification and Validation for Molecular Diagnostic Assays
Halling, K. C., Schrijver, I., & Persons, D. L. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0212-ed · Cited by 57
Mutations in BRCA1 from Fixed, Paraffin-Embedded Tissue Can Be Artifacts of Preservation
Wong, C., DiCioccio, R. A., Allen, H. J., Werness, B. A., & Piver, M. S. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(98)00079-x · Cited by 54
The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing
Naoki, K., Soejima, K., Okamoto, H., Hamamoto, J., Hida, N., Nakachi, I., Yasuda, H., Nakayama, S., Yoda, S., Satomi, R., et al. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0187-5 · Cited by 54
Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung
Park, S. H., Ha, S. Y., Lee, J.-I., et al. (2009) · Journal of Korean Medical Science · doi:10.3346/jkms.2009.24.3.448 · Cited by 54
Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer
Gandara, D. R., Grimminger, P., Mack, P. C., Lara, P. N., Li, T., Danenberg, P. V., & Danenberg, K. D. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fd418d · Cited by 52
Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer
Oshita, F., Matsukuma, S., Yoshihara, M., Sakuma, Y., Ohgane, N., Kameda, Y., Saito, H., Yamada, K., Tsuchiya, E., & Miyagi, Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603396 · Cited by 52
ALK-Rearranged Lung Cancer: Adenosquamous Lung Cancer Masquerading as Pure Squamous Carcinoma
Chaft, J. E., Rekhtman, N., Ladanyi, M., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824c9485 · Cited by 51
Self-citation
Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?
Ahn, M., Park, B.-B., Ahn, J. S., Kim, S. W., Kim, H., Lee, J. S., Kang, J., Choi, Y., SONG, H. S., Park, S. H., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4608 · Cited by 50
Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma
Hasanovic, A., Ang, D. C., Moreira, A. L., & Zakowski, M. F. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.004 · Cited by 50
An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients
Kawada, I., Soejima, K., Watanabe, H., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318186fadd · Cited by 49
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
Satouchi, M., Negoro, S., Funada, Y., Urata, Y., Shimada, T., Yoshimura, S., Kotani, Y., Sakuma, T., Watanabe, H., Adachi, S., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603710 · Cited by 47
Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer
Chen, C., Chang, J. W., Cheung, Y., et al. (2008) · Acta Radiologica · doi:10.1080/02841850802294410 · Cited by 46
Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors
Rickman, O. B., Vohra, P. K., Sanyal, B., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2549 · Cited by 46
Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells
Fan, X., Furnari, F. B., Cavenee, W. K., et al. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.5.1023 · Cited by 45
High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma
Moiseyenko, V. M., Procenko, S. A., Levchenko, E., et al. (2010) · Onkologie · doi:10.1159/000302729 · Cited by 44
ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung Adenocarcinoma
Janne, P. A., & Meyerson, M. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4197 · Cited by 43
Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma
Ohtsuka, K., Ohnishi, H., Furuyashiki, G., Nogami, H., Koshiishi, Y., Ooide, A., Matsushima, S., Watanabe, T., & Goya, T. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30407-x · Cited by 43
Mutation Detection of Epidermal Growth Factor Receptor and KRAS Genes Using the Smart Amplification Process Version 2 from Formalin-Fixed, Paraffin-Embedded Lung Cancer Tissue
Miyamae, Y., Shimizu, K., Mitani, Y., Araki, T., Kawai, Y., Baba, M., Kakegawa, S., Sugano, M., Kaira, K., Lezhava, A., et al. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090105 · Cited by 43
EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib
Xu, J., Han, Y., Duan, H. Q., Gao, E., Zhang, Y., Liu, X., Zhang, J. S., Toschi, L., Galetta, D., Azzariti, A., et al. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0512-1 · Cited by 42
Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer
Araki, J., Okamoto, I., Suto, R., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.10.012 · Cited by 42
Detection of EGFR Gene Mutations Using the Wash Fluid of CT-Guided Biopsy Needle in NSCLC Patients
Otani, H., Toyooka, S., Soh, J., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31816de2cd · Cited by 41
Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas
Dahse, R., Driemel, O., Schwarz, S., Dahse, J., Kromeyer-Hauschild, K., Berndt, A., & Kosmehl, H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604875 · Cited by 39
Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?
Stinchcombe, T. E., & Socinski, M. A. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0019 · Cited by 39
Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery
Kondo, M., Yokoyama, T., Fukui, T., Yoshioka, H., Yokoi, K., Nagasaka, T., Imaizumi, K., Kume, H., Hasegawa, Y., Shimokata, K., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.06.008 · Cited by 38
Design and Analytical Validation of Clinical DNA Sequencing Assays
Pont-Kingdon, G. A., Gedge, F. E. H., Wooderchak‐Donahue, W. L., et al. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2010-0623-oa · Cited by 38
Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy
Endo, K., Sasaki, H., Yano, M., Kobayashi, Y., Yukiue, H., Haneda, H., Suzuki, E., Kawano, O., & Fujii, Y. (2006) · Oncology Reports · doi:10.3892/or.16.3.533 · Cited by 37
Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry
Harada, T., López-Chávez, A., Xi, L., Raffeld, M. A., Wang, Y., & Giaccone, G. (2010) · Oncogene · doi:10.1038/onc.2010.545 · Cited by 37
Self-citation
Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer
Morinaga, R., Okamoto, I., Fujita, Y., Arao, T., Sekijima, M., Nishio, K., Ito, H., Fukuoka, M., Kadota, J., & Nakagawa, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00962.x · Cited by 37
The Effects of Tissue Fixation Alternatives on DNA Content
Baloglu, G., Haholu, A., Küçükodacı, Z., et al. (2008) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e31815dffa6 · Cited by 37
Impact of HER2 and EGFR gene status on gefitinib‐treated patients with nonsmall‐cell lung cancer
Soh, J., Toyooka, S., Ichihara, S., Fujiwara, Y., Hotta, K., Suehisa, H., Kobayashi, N., Ichimura, K., Aoe, K., Aoe, M., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22818 · Cited by 33
EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy
Thunnissen, E., Bovée, J. V. M. G., Bruinsma, H., van den Brule, A. J. C., Dinjens, W. N. M., Heideman, D. A. M., Meulemans, E. V., Nederlof, P. M., van Noesel, C. J. M., Prinsen, C., et al. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200163 · Cited by 33
Self-citation
Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Without Testing for Epidermal Growth Factor Receptor (EGFR) Mutations
Wu, J., Shih, J., Chen, K., et al. (2011) · Medicine · doi:10.1097/md.0b013e31821a16f4 · Cited by 31
EGFR Mutations are More Frequent in Well-Differentiated than in Poor-Differentiated Lung Adenocarcinomas
Liu, Y., Xu, M., Zhong, H., et al. (2008) · Pathology & Oncology Research · doi:10.1007/s12253-008-9113-1 · Cited by 31
Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH: Erratum
(2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318215ba35 · Cited by 30
Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
Garassino, M. C., Borgonovo, K., Rossi, A., et al. (2009) · PubMed · Cited by 29
Biological Prognostic and Predictive Factors in Lung Cancer
Rossi, A., Galetta, D., & Gridelli, C. (2009) · Oncology · doi:10.1159/000258500 · Cited by 29
A Simple and Sensitive Method for Detecting Major Mutations Within the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Gene in Non???small-cell Lung Carcinoma
Ohnishi, H., Ohtsuka, K., Ooide, A., Matsushima, S., Goya, T., & Watanabe, T. (2006) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200606000-00007 · Cited by 29
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Mitsudomi, T. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70194-2 · Cited by 28
EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients
Wang, Z., Wu, Y.-L. L. C., Zhang, G. C., Zhou, Q., Xu, C., & Guo, A. (2008) · Onkologie · doi:10.1159/000116736 · Cited by 25
Design and Analytic Validation of BCR-ABL1 Quantitative Reverse Transcription Polymerase Chain Reaction Assay for Monitoring Minimal Residual Disease
Jennings, L. J., Smith, F. A., Halling, K. C., Persons, D. L., Kamel‐Reid, S., & _, _. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0136-oa · Cited by 24
Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients
Sueoka, N., Sato, A., Eguchi, H., Komiya, K., Sakuragi, T., Mitsuoka, M., Satoh, T., Hayashi, S., Nakachi, K., & Sueoka, E. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0144-2 · Cited by 24
Validation of KRAS Testing for Anti-EGFR Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma
Kamel‐Reid, S., Zhang, T., Persons, D. L., Nikiforova, M. N., Halling, K. C., & _, _. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0220-oa · Cited by 23
Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets
Lee, K. H., Kim, S., Suh, C., Han, Y. H., & Lee, J. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1280-6 · Cited by 23
Epidermal growth factor receptor mutations detected by denaturing high‐performance liquid chromatography in nonsmall cell lung cancer
Cohen, V., Agulnik, J. S., Ang, C., Kasymjanova, G., Batist, G., Small, D. I., Brandao, G., Chong, G., & Miller, W. H. (2010) · Cancer · doi:10.1002/cncr.25214 · Cited by 22
Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine
Pas, T. M. D., de Braud, F., Mandalà, M., et al. (2001) · Lung Cancer · doi:10.1016/s0169-5002(00)00176-8 · Cited by 20
Performance of Whole-Genome Amplified DNA Isolated from Serum and Plasma on High-Density Single Nucleotide Polymorphism Arrays
Croft, D. T., Jordan, R. M., Patney, H. L., et al. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070155 · Cited by 19
Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story
Argiris, A. E., Hensing, T. A., Yeldandi, A. V., et al. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31513-6 · Cited by 18
Validation of Fluorescence In Situ Hybridization Using an Analyte-Specific Reagent for Detection of Abnormalities Involving the Mixed Lineage Leukemia Gene
Saxe, D., Persons, D. L., Wolff, D. J., et al. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2010-0645-sa · Cited by 18
Rapid and Efficient Detection of EGFR Mutations in Problematic Cytologic Specimens by High-Resolution Melting Analysis
Hlinkova, K., Babál, P., Berzinec, P., Majer, I., & Ilenčíková, D. (2011) · Molecular Diagnosis & Therapy · doi:10.1007/bf03257190 · Cited by 15
Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer
Casorzo, L., Corigliano, M., Ferrero, P., et al. (2009) · Diagnostic Pathology · doi:10.1186/1746-1596-4-36 · Cited by 15
Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.
Choi, D. R., Lee, K. H., Choi, C., Kim, S., Suh, C., & Lee, J. (2011) · PubMed · Cited by 14
PCR-based testing for therapy-related EGFR mutations in patients with non-small cell lung cancer.
Dahse, R., Berndt, A., & Kosmehl, H. (2008) · PubMed · Cited by 14
Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non???Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story
Argiris, A. E., Hensing, T. A., Yeldandi, A. V., et al. (2006) · Journal of Thoracic Oncology · doi:10.1097/01243894-200601000-00011 · Cited by 10
A comparative study of EGFR mutation screening methods in non-small cell carcinoma of lung
Gombos, Z., Danihel, L., Puttaswamy, K., et al. (2010) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/bf03657301 · Cited by 6

Research works printed but not linked: 1

Department of Health and Human Services, 1992, Clinical laboratory improvement amendments of 1988: final rule, Fed Regist, 57, 7001

Sorted by citations

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Self-citation
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Towards precision medicine
Ashley, E. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.86 · Cited by 1,116
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., Lew, M., Pantelas, J., Ramalingam, S. S., Reck, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7293 · Cited by 492
Non–Small Cell Lung Cancer, Version 6.2015
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0071 · Cited by 478

See all 1,280

Authors: Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., Thunnissen, E., & Ladanyi, M.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Lindeman, Neal I.
Beasley, Mary Beth
Chitale, Dhananjay Arun
Giaccone, Giuseppe
Jenkins, Robert Brian
Kwiatkowski, David J.
Squire, Jeremy
Thunnissen, Erik
Ladanyi, Marc
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2013-07
Volume: 8
Issue: 7
Pages: 823-859
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1097/jto.0b013e318290868f
PMC: PMC4159960
OpenAlex: W1978236936
Cited by: 1,280
References: 322
Citations by year: 2026: 17 · 2025: 17 · 2024: 33 · 2023: 42 · 2022: 52 · 2021: 81 · 2020: 99 · 2019: 78 · 2018: 135 · 2017: 164 · 2016: 170 · 2015: 167 · 2014: 168 · 2013: 54
FWCI: 151.45
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 868 d)
Locations: Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
PubMed Central (acceptedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Cancer Institute (P01CA129243)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: lung cancer, EGFR mutation, ALK fusion, tyrosine kinase inhibitors, molecular testing, patient selection, predictive biomarkers, targeted therapy, molecular pathology
MeSH terms: Anaplastic Lymphoma Kinase, Systematic Reviews as Topic, Expert Testimony, Genetic Testing, Humans, International Agencies, Lung Neoplasms, Mutation, Societies, Medical, Biomarkers, Tumor, Gene Rearrangement, Patient Selection, Evidence-Based Medicine, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks